BR112022000553A2 - Compostos moduladores do receptor de estrogênio - Google Patents
Compostos moduladores do receptor de estrogênioInfo
- Publication number
- BR112022000553A2 BR112022000553A2 BR112022000553A BR112022000553A BR112022000553A2 BR 112022000553 A2 BR112022000553 A2 BR 112022000553A2 BR 112022000553 A BR112022000553 A BR 112022000553A BR 112022000553 A BR112022000553 A BR 112022000553A BR 112022000553 A2 BR112022000553 A2 BR 112022000553A2
- Authority
- BR
- Brazil
- Prior art keywords
- estrogen receptor
- compounds
- modulating compounds
- receptor modulating
- estrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
compostos moduladores do receptor de estrogênio. a presente invenção refere-se a compostos que são moduladores do receptor de estrogênio. estão também descritas as composições farmacêuticas e os medicamentos que incluem compostos descritos aqui no presente, como também métodos de usar tais moduladores do receptor de estrogênio, sós ou em combinação com outros compostos, para tratar doenças ou condições que são mediadas ou dependentes de receptores de estrogênio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876963P | 2019-07-22 | 2019-07-22 | |
| PCT/US2020/042903 WO2021016254A1 (en) | 2019-07-22 | 2020-07-21 | Estrogen receptor-modulating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000553A2 true BR112022000553A2 (pt) | 2022-05-17 |
Family
ID=71995156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000553A BR112022000553A2 (pt) | 2019-07-22 | 2020-07-21 | Compostos moduladores do receptor de estrogênio |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220281875A1 (pt) |
| EP (1) | EP4003996A1 (pt) |
| JP (1) | JP2022541610A (pt) |
| KR (1) | KR20220035942A (pt) |
| CN (1) | CN114174297B (pt) |
| AU (1) | AU2020315812A1 (pt) |
| BR (1) | BR112022000553A2 (pt) |
| CA (1) | CA3146365A1 (pt) |
| IL (1) | IL289869A (pt) |
| MX (1) | MX2022000520A (pt) |
| WO (1) | WO2021016254A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113105329B (zh) * | 2021-04-22 | 2023-10-03 | 成都道合尔医药技术有限公司 | 一种(e)-甲酯3-(3,5-二氟-4-甲酰基苯基)丙烯酸的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2300857B (en) * | 1995-05-19 | 1998-07-08 | Pharmacia Spa | Indazole [3,2-e] -pyrrole and 1,2,3 -benzotriazole [3,2-e] -pyrrole derivatives |
| SG11202006942WA (en) * | 2018-01-22 | 2020-08-28 | Radius Pharmaceuticals Inc | Estrogen receptor-modulating compounds |
-
2020
- 2020-07-21 BR BR112022000553A patent/BR112022000553A2/pt unknown
- 2020-07-21 CA CA3146365A patent/CA3146365A1/en active Pending
- 2020-07-21 US US17/629,041 patent/US20220281875A1/en active Pending
- 2020-07-21 EP EP20753619.4A patent/EP4003996A1/en active Pending
- 2020-07-21 MX MX2022000520A patent/MX2022000520A/es unknown
- 2020-07-21 KR KR1020227005429A patent/KR20220035942A/ko unknown
- 2020-07-21 JP JP2022504176A patent/JP2022541610A/ja active Pending
- 2020-07-21 AU AU2020315812A patent/AU2020315812A1/en active Pending
- 2020-07-21 WO PCT/US2020/042903 patent/WO2021016254A1/en unknown
- 2020-07-21 CN CN202080051792.9A patent/CN114174297B/zh active Active
-
2022
- 2022-01-16 IL IL289869A patent/IL289869A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220035942A (ko) | 2022-03-22 |
| WO2021016254A1 (en) | 2021-01-28 |
| MX2022000520A (es) | 2022-02-10 |
| CN114174297B (zh) | 2024-07-12 |
| AU2020315812A1 (en) | 2022-03-17 |
| CN114174297A (zh) | 2022-03-11 |
| IL289869A (en) | 2022-03-01 |
| JP2022541610A (ja) | 2022-09-26 |
| EP4003996A1 (en) | 2022-06-01 |
| US20220281875A1 (en) | 2022-09-08 |
| CA3146365A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014014124A2 (pt) | Moduladores do receptor de estrogênio fluorados e usos dos mesmos | |
| CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
| BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
| PH12020550523A1 (en) | Modulators of the integrated stress pathway | |
| BR112015022566A2 (pt) | composto e composição farmacêutica | |
| PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
| BR112012020558A2 (pt) | moduladores do receptor de androgênio e seus usos | |
| BR112021021703A2 (pt) | Cicloalquilas substituídas como moduladores da via de estresse integrada | |
| BR112019006876A2 (pt) | anticorpos e composições anti-lag-3 | |
| CY1120450T1 (el) | Διαμορφωτες υποδοχεων οιστρογονων και χρησεις εξ'αυτων | |
| MX2021013193A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| BR112019000692A2 (pt) | moduladores de somatostatina e usos destes | |
| BR112015001801A2 (pt) | métodos e composições para determinar a resistência à terapia de receptor de androgênio | |
| EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| BR112017024555A2 (pt) | moduladores de ccr2 | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| CL2019001129A1 (es) | Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y. | |
| ECSP088852A (es) | Azolopirimidinas como inhibidores de la actividad canabinoidea 1 | |
| BR112018016689A2 (pt) | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m1 | |
| BR112017006299A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil |